AHA 2026 Closes With Smartwatch AI, Resistant Hypertension Data, and a 10-Year Coronary Trial

Five stories from the past 72 hours: the final day of the American Heart Association's Scientific Sessions in Chicago delivers a home-monitoring first; a novel blood-pressure drug confirms long-term durability; a decade-long cardiology trial reaches its reckoning; and two public-health signals — a measles milestone and a bird flu death — demand attention beyond the cardiology floor.

Sunday, 9 November: WATCH-LV — A Consumer Smartwatch Detects Silent Heart Failure at Home

The last wave of late-breaking science at AHA Scientific Sessions 2026 includes WATCH-LV, a cross-manufacturer validation and serial home-monitoring study of an AI-enabled electrocardiogram algorithm running on consumer smartwatches. The trial asked whether a wrist-worn device could accurately flag left ventricular systolic dysfunction (LVSD) — the form of heart failure in which the heart's main pumping chamber weakens and ejects less than 40 percent of its blood with each beat — without a clinic visit, a 12-lead ECG, or an echocardiogram.

The algorithm, drawing on a single-lead ECG strip of the kind any Apple Watch or comparable device can capture in 30 seconds, showed high discriminatory accuracy for LVSD across different smartwatch brands in the cross-manufacturer validation arm. The home-monitoring component tracked whether serial recordings over weeks improved sensitivity, allowing the algorithm to catch intermittent dysfunction that a one-time clinic recording might miss. Supporting pilot data from an earlier Korean study reported a median AI-ECG score of 57 in patients with confirmed LVSD versus 5 in those without — a wide separation that suggests the algorithm is not simply picking up borderline signal.

The clinical significance is substantial. LVSD is frequently asymptomatic until it has progressed to a stage requiring hospitalisation. Conventional screening relies on echocardiography — costly, operator-dependent, and inaccessible in many primary-care settings. A validated wrist-based approach would allow cardiologists to tier high-risk patients for formal imaging while monitoring recovery or deterioration in those already diagnosed. Stage of evidence: late-breaking trial, conference presentation; peer-reviewed publication expected.

Saturday, 8 November: Lorundrostat Keeps Resistant Hypertension Controlled at 48 Weeks

Mineralys Therapeutics presented 48-week open-label extension data from its Transform-HTN trial at AHA 2026, showing that lorundrostat sustained the blood pressure reductions seen at 12 weeks, with no new clinically meaningful safety signals over the 36-week extension period.

Lorundrostat is an aldosterone synthase inhibitor — a drug class that blocks the enzyme responsible for producing aldosterone, a hormone that raises blood pressure by instructing the kidneys to retain sodium and water. Unlike older mineralocorticoid receptor blockers such as spironolactone, lorundrostat works upstream, directly reducing the body's aldosterone output rather than simply blocking its receptor. This distinction may matter for patients who over-produce aldosterone because of adrenal overactivity rather than receptor hypersensitivity.

The pivotal Launch-HTN data reported earlier showed that 46 percent of participants with uncontrolled or resistant hypertension achieved an office systolic blood pressure below 130 mmHg at 12 weeks on the 50 mg dose — a clinically meaningful threshold for cardiovascular risk reduction. The 48-week extension confirms that effect is not fleeting. Mineralys has a PDUFA date of December 22, 2026, meaning the FDA decision on approval is weeks away. Stage of evidence: open-label extension of pivotal trials; regulatory decision pending.

Saturday–Sunday, 8–9 November: ISCHEMIA-EXTEND Delivers Its 10-Year Verdict on Stents vs. Medication

One of interventional cardiology's most consequential ongoing debates reaches its final chapter at AHA 2026. NYU Langone's team presented the complete, long-term survival analysis from ISCHEMIA-EXTEND, tracking patients with stable coronary artery disease and abnormal stress tests for a median of approximately ten years after randomisation to either an invasive strategy (coronary stenting or bypass surgery followed by medical therapy) or a conservative strategy (medical therapy alone, with invasive intervention reserved for clinical deterioration).

The original ISCHEMIA trial published in 2020 found no difference in the composite cardiovascular outcome between the two strategies at a median follow-up of 3.2 years. A 2022 interim ISCHEMIA-EXTEND report noted that all-cause mortality had converged, with a potential trade-off: fewer cardiovascular deaths but more non-cardiovascular deaths in the invasive group. The 10-year final read presented at AHA 2026 represents the most mature evidence cardiologists will have on this question for some time.

A companion analysis covers ISCHEMIA-CKD EXTEND, which follows the subset of patients with advanced chronic kidney disease — including those on dialysis — a population whose management differs substantially given higher baseline procedural risk. The clinical ramification for the broader population is straightforward: for the many patients with stable symptoms and controlled risk factors, the extended data will either reinforce the case for a medication-first approach or identify a subgroup — possibly defined by ischaemia severity, anatomy, or kidney function — that does derive a survival benefit from early intervention. Stage of evidence: pre-specified long-term follow-up of a randomised controlled trial; simultaneous journal publication expected.

Week of 3–9 November: US Measles Passes 5,000 Cases — Worst Year Since 1991

Data published by the CDC and reported in Contagion Live's November 6, 2026 update show 5,182 confirmed measles cases in the United States year-to-date as of November 5, a 6.8 percent jump from the previous week and more than double the 2,289 cases recorded for all of 2025. The figure surpasses the previous post-1991 record and is approaching levels not seen since before the elimination of endemic measles transmission in the United States in 2000.

Death counts remain contested. State health departments have reported eight measles-associated deaths in 2026, while the CDC's official national count is four — a discrepancy that stems from a methodological change in how the agency attributes mortality to measles, switching from real-time state reporting to data from the National Center for Health Statistics, a process that lags weeks to months. Pennsylvania alone has reported five deaths; the CDC has not recognised all of them.

The outbreak pattern reflects a continued erosion of childhood vaccination coverage in certain communities and geographic areas. Measles requires about 95 percent population immunity to interrupt transmission; pockets below that threshold have allowed the virus to circulate in unvaccinated clusters. The CDC, the American Academy of Pediatrics, and the World Health Organization have each called for catch-up vaccination campaigns. For clinicians in Cyprus, Greece, and neighbouring eastern Mediterranean countries, where vaccination coverage has also slipped since 2020: measles is not a relic — imported cases follow travel routes, and the US outbreak is a live reminder.

Sunday, 2 November: US Bird Flu Death — First H5N1 Fatality in About a Year, Linked to Dairy Cattle

A Yakima County, Washington resident died on November 2 after contracting H5N1 avian influenza following exposure to infected dairy cattle, according to state and local health officials. The person had underlying health conditions and was hospitalised before death; the CDC confirmed the H5N1 strain by genetic sequencing. This is the second H5N1 death in Washington state within roughly twelve months (the first was in November 2025 and involved the rarer H5N5 subtype; Louisiana reported a separate H5N1 fatality in January 2025).

The CDC's genomic analysis found no changes in the virus that would indicate easier human-to-human transmission or increased virulence. No person-to-person spread has been identified; three total human infections have been linked to the affected Yakima County dairy, and 33 herds in the county have recently tested positive for H5N1. The Yakima Health District and the Washington State Department of Health are monitoring all close contacts.

The CDC continues to rate the general public risk as low. That assessment is calibrated to the current evidence of sporadic zoonotic spillover without sustained human chains; it is not a statement about the virus's pandemic potential, which remains a subject of active surveillance. For clinical staff in agricultural communities and farm workers in dairy or poultry settings: the exposure pathway here — close, unprotected contact with infected animals — is consistent with every prior US case, and appropriate personal protective equipment remains the primary risk-mitigation tool. Stage of evidence: confirmed epidemiological case report; surveillance ongoing.

---

This article is produced for journalistic and informational purposes only and does not constitute medical advice. Readers should consult a qualified clinician or pharmacist before making any change to their medication, diet, or health regimen.